GSK plc

GSK plc reported that Maya Martinez-Davis, President, US, acquired American Depositary Shares (ADS) as part of her GSK Executive Supplemental Savings Plan account. The transaction involved 9.016 ADSs at a price of $52.9600 per ADS. This acquisition took place on August 7, 2026, on the New York Stock Exchange.

GSK plc has reported its total voting rights as of July 31, 2026. The company's issued share capital consisted of 4,316,292,310 shares, with 270,881,064 Ordinary Shares held in Treasury. Consequently, the total number of voting rights in the company is 4,045,411,246, a figure shareholders can use for regulatory notification purposes.

GSK plc reported that Regis Simard, President of Global Supply Chain, sold 38,000 Ordinary Shares on July 29, 2026. The transaction took place on the London Stock Exchange at a price of £20.3800 per share, totaling approximately £774,440. This was an initial notification of a Person Discharging Managerial Responsibilities (PDMR) shareholding transaction.

GSK's licensor, Hansoh Pharmaceutical Group Co., Ltd., announced positive results from a second Phase III trial (ARTEMIS-011) for risvutatug rezetecan (Ris-Rez) in China. The study met its primary endpoint of progression-free survival in patients with relapsed osteosarcoma, demonstrating statistically significant and clinically meaningful improvements compared to chemotherapy. This adds to previous positive data in small-cell lung cancer, strengthening confidence in Ris-Rez, which GSK is developing globally for various tumor types, including lung and prostate cancers.

GSK announced a significant investment of £400 million over three years to accelerate its R&D pipeline in the UK. This includes establishing a new 300,000 square foot R&D site on the Cambridge Biomedical Campus, which will house over 1,000 scientists and focus on key therapeutic areas. The company will vacate its Stevenage R&D site by 2029 and upgrade its existing R&D labs at Ware, Hertfordshire, to create integrated drug development capabilities. This strategic move aims to integrate GSK further into a world-leading life sciences ecosystem.

GSK plc reported strong Q2 2026 core results, with total sales reaching £8.4 billion, a 5% increase at constant exchange rates (CER), driven by robust performance in Specialty Medicines and Vaccines. Core operating profit grew 7% CER to £2.8 billion, and Core EPS increased by 9% CER to 50.5p. The company announced plans to accelerate R&D, expecting over 20 phase III trial starts in 2026, and initiated a 3-year "Accelerate Growth" program targeting £1.9 billion in annual savings by 2029. GSK reaffirmed its full-year 2026 guidance and declared a Q2 dividend of 17p per share.

GSK plc reported that Maya Martinez-Davis, President, US, acquired 9.407 American Depositary Shares (ADS) on July 22, 2026. The acquisition was made at a price of $50.76 per ADS and was part of her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange.

GSK plc announced the admission of 70,759 ordinary shares to trading on the London Stock Exchange's Main Market. These shares, with a nominal value of 31¼ pence each, are fully fungible with existing ordinary shares. The admission is in connection with the GlaxoSmithKline plc Share Save Plan 2022 and covers the period from May 29, 2026, to July 24, 2026. Following this admission, the total number of ordinary shares admitted to trading is 4,316,292,310.

GSK plc announced that the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received a prior ROS1 kinase inhibitor. This approval, which came ahead of schedule, is based on the ARROS-1 phase I/II clinical trial, showing meaningful and durable responses, including in patients with brain metastases. Jideytro, acquired through the Nuvalent, Inc. acquisition, marks GSK's first approved lung cancer medicine and supports its strategy to improve standards of care.

GSK announced that the European Medicines Agency (EMA) has accepted a submission to update the label for its vaccine, Bexsero. This update proposes including a single-dose booster for individuals aged 10 years and older who were previously vaccinated with Bexsero. If approved, this booster could enhance protection against Invasive Meningococcal Disease (IMD) and potentially reduce its burden in regions with existing infant MenB programs.